Defiance Debuts Nasdaq Junior Biotechnology ETF (IBBJ)
Defiance ETFs debuted a new ETF today with targeted exposure to the junior disruptors in the biotech space. Defiance ETFs LLC announced the launch of the Defiance Nasdaq Junior Biotechnology ETF...
View ArticleNew Biotech ETF Taps Into Small But Mighty Theme
Extending what’s been a busy stretch of unique healthcare ETF launches, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) debuted on Tuesday, coming to market at a time when biotechnology ETFs,...
View ArticleA Junior Biotech ETF With Home Run Potential
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is one of the newest exchange traded funds on the market and it could be one of the most appropriate for the current environment. IBBJ’s 176 member...
View ArticleETF of the Week: Defiance Nasdaq Junior Biotechnology ETF (IBBJ)
ETF Trends CEO Tom Lydon discussed the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show. IBBJ covers companies around the...
View ArticleSmall-Cap Biotechnology ETF Brings Big Opportunity
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is still in its infancy in the biotechnology ETFs arena, having debuted just last month, but a big opportunity comes with this rookie ETF. IBBJ...
View ArticleDefiance ETFs Launches the First SPAC ETF
SPACs give emerging companies both flexibility and control, while investors finally have open access to some of the biggest investment deals in the market. Expanding on this concept, Defiance ETFs has...
View ArticleYoung But Hungry: A New Defiance ETF is Defying Expectations
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is just a few months in, but it’s already asserting itself in the biotechnology exchange traded funds arena, one teeming with competition. IBBJ...
View ArticleConsider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021
After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded...
View ArticleWhy Small Cap Biotech ETFs Are Still Brilliant Bets
Small cap stocks are retreating. So are biotechnology names. Yet this combo could be an attractive invitation to examine with the Defiance Nasdaq Junior Biotechnology ETF (IBBJ). IBBJ, which debuted...
View ArticleBet on Biotech Small Caps to Bounce Back
Large cap biotechnology have strengthened in recent months, but smaller counterparts are still waiting on their 2021 moment. When that happens, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) could...
View ArticleBiotech ETFs Are Already Benefitting from Pfizer Vaccine’s Full Approval
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be...
View ArticleWhen Will Smaller Biotech Firms Get Their Big Break?
Smaller biotechnology stocks aren’t setting the world on fire this year, but some analysts believe it’s a matter of when, not if, that situation reverses. Should small biotechnology names get their...
View ArticleCould Biotech ETFs Get Another Boost From JNJ News?
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials....
View ArticleBiotech ETFs Benefit From Moderna Dual Booster Shot News
As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it’s creating a dual-purpose vaccine booster shot that...
View ArticleCould Biotech ETFs Be Due For More Upside?
Despite suffering significant losses recently, biotechnology stocks and ETFs have seen some impressive gains over the last year or so, as coronavirus vaccines have propelled companies like Pfizer and...
View Article
